Meeting
2018 ASCO Annual Meeting
A multicenter phase II study of low-dose erlotinib in frail patients with EGFR mutation-positive, non-small cell lung cancer: Thoracic oncology research group (TORG) trial 1425.
Authors
Kazuhiko Yamada
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
Kazuhiko Yamada , Shingo Miyamoto , Koichi Azuma , Hidenobu Ishii , Akihiro Bessho , Nobuaki Fukamatsu , Hideo Kunitoh , Mari Ishii , Hiroshi Tanaka , Hiromi Aono , Yoshiro Nakahara , Kei Kusaka , Yukio Hosomi , Norihiro Kikuchi , Yoshiaki Mori , Hidetoshi Itani , Takashi Kasai , Masao Ichiki , Nobuhiko Seki , Hiroaki Okamoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
UMIN 000015949
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9063)
DOI
10.1200/JCO.2018.36.15_suppl.9063
Abstract #
9063
Poster Bd #
386
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
First Author: Jamie E. Chaft
Poster
2022 ASCO Annual Meeting
A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutation.
First Author: Youngjoo Lee
Poster
2022 ASCO Annual Meeting
Adjuvant icotinib versus observation in patients with completely resected, EGFR-mutated, stage IB non–small cell lung cancer (GASTO1003, CORIN): A randomized phase II trial.
First Author: Ning Li
Poster
2018 ASCO Annual Meeting
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
First Author: Julien Mazieres